Almost exactly three years after agreeing on a $2.6 billion deal to acquire Aimmune Therapeutics and its peanut allergy therapy Palforzia, food group Nestle has sold off the business. This morning ...

Nestle itself had acquired the drug in a $2.1bn buyout of Aimunne Therapeutics, the peanut allergy treatment’s original developer. Nestle’s decision to sell Palforzia stemmed from slow uptake ...